cfdb.eu

CFDB - Cystic Fibrosis DataBase

primary studies published RCT

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.

Year: 2021
Date: 2021
Author: Griese M

Keywords: Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; elexacaftor; Trikafta;

Back

CFDB - Cystic Fibrosis DataBase

Search (?)

Quick menu

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.

Source

SIFC - Societa' Italiana Fibrosi Cistica

Lega Italiana Fibrosi Cistica ONLUS